Rajaie Cardiomyopathy and Myocarditis Registry

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04304118

Enrollment

6000

Registered

2020-03-11

Start date

2019-11-11

Completion date

2025-11-11

Last updated

2020-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Characteristics, Current Therapeutic Approaches, Long-term Outcomes, Natural History

Brief summary

The prevalence of patients with cardiomyopathies who referred to Rajaei Cardiovascular medical and research center is remarkable, and also the mission of this center is to achieve center of excellence in the field of cardiomyopathy. Rajaie Cardiomyopathy and myocarditis Registry study is an observational registry of consecutive patients with four cardiomyopathy subtypes: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM) as well as myocarditis designed to determine clinical characteristics, natural history, current therapeutic approaches, response to treatment and long-term outcomes of patients with cardiomyopathy and myocarditis and to address limitations in extant evidence to improve prognostication in cardiomyopathies and myocarditis. Prediction of mortality and response to different treatments in these patients using artificial intelligence is another aim of this registry

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to No maximum

Healthy volunteers

Inclusion criteria

1. age greater than one year 2. documented cardiomyopathy/ myocarditis fulfilling standard diagnostic criteria 3. able to give informed consent or in the case of child consent from a parent

Exclusion criteria

Patients who have not consent to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Admissions to hospital	1 year	Number of hospitalizations for cardiovascular reasons
Development of chronic heart failure	1 year	significant decrease in left ventricular ejection fraction
Prevalence of Stroke/Transient ischemic attack	1 year	At least 80% CT/MRI verification of the diagnosis of ischemic stroke/Transient ischemic attack, within the first week of stroke onset
Incidence of sudden death	1 year	unexpected death from a cardiovascular cause in a person with or without preexisting heart disease
Incidence of heart trasplantation	1 year	Cardiac transplantation in patients with end-stage HF who remain symptomatic despite optimal medical therapy

Secondary

Measure	Time frame	Description
response to current therapeutic approaches	1 year	Implantable cardioverter defibrillator implantation, Cardiac resynchronisation therapy, septal myectomy, ablation, cardiac transplantation and medications

Countries

Iran

Contacts

Primary ContactBehshid Ghadrdoost, PhD

behshid.ghadrdoost@yahoo.com+982123923017

Outcome results